AU2021301264A1 - Compounds having antibacterial activity - Google Patents

Compounds having antibacterial activity Download PDF

Info

Publication number
AU2021301264A1
AU2021301264A1 AU2021301264A AU2021301264A AU2021301264A1 AU 2021301264 A1 AU2021301264 A1 AU 2021301264A1 AU 2021301264 A AU2021301264 A AU 2021301264A AU 2021301264 A AU2021301264 A AU 2021301264A AU 2021301264 A1 AU2021301264 A1 AU 2021301264A1
Authority
AU
Australia
Prior art keywords
group
heteroaryl
aryl
alkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021301264A
Other languages
English (en)
Inventor
Connor CHAIN
Xueming Chen
Zemer Gitai
Yong Huang
Chenran JIANG
Hahn Kim
Shuo Li
James K. Martin
Joseph P. SHEEHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peking University Shenzhen Graduate School
Princeton University
Original Assignee
Peking University Shenzhen Graduate School
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peking University Shenzhen Graduate School, Princeton University filed Critical Peking University Shenzhen Graduate School
Publication of AU2021301264A1 publication Critical patent/AU2021301264A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2021301264A 2020-07-02 2021-07-01 Compounds having antibacterial activity Pending AU2021301264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047612P 2020-07-02 2020-07-02
US63/047,612 2020-07-02
PCT/US2021/040143 WO2022006432A1 (en) 2020-07-02 2021-07-01 Compounds having antibacterial activity

Publications (1)

Publication Number Publication Date
AU2021301264A1 true AU2021301264A1 (en) 2023-02-02

Family

ID=79314944

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021301264A Pending AU2021301264A1 (en) 2020-07-02 2021-07-01 Compounds having antibacterial activity
AU2021299504A Pending AU2021299504A1 (en) 2020-07-02 2021-07-01 Compounds having anticancer activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021299504A Pending AU2021299504A1 (en) 2020-07-02 2021-07-01 Compounds having anticancer activity

Country Status (7)

Country Link
US (2) US20230295164A1 (enExample)
EP (2) EP4175953A4 (enExample)
JP (2) JP2023532128A (enExample)
CN (2) CN115867354B (enExample)
AU (2) AU2021301264A1 (enExample)
CA (2) CA3183770A1 (enExample)
WO (2) WO2022006447A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024531898A (ja) * 2021-08-17 2024-09-03 サウスウエスト リサーチ インスティテュート コロナウイルスに対する阻害剤
US20260138981A1 (en) * 2022-10-07 2026-05-21 The Trustees Of Princeton University Dihydrofolate reductase inhibitors for anti-biotic resistant infections
CN118047780A (zh) * 2022-11-09 2024-05-17 中国医学科学院药物研究所 一类喹唑啉杂环化合物及其抗感染和抗肿瘤的应用
CN119661535B (zh) * 2023-09-21 2026-03-20 中国医学科学院药物研究所 7H-吡咯并[3,2-f]喹唑啉衍生物及其抗感染应用
WO2025195460A1 (zh) * 2024-03-22 2025-09-25 深圳湾实验室坪山生物医药研发转化中心 稠环衍生物
CN121013722A (zh) * 2024-03-22 2025-11-25 深圳湾实验室坪山生物医药研发转化中心 结核病的预防与治疗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE45427B1 (en) * 1976-07-09 1982-08-25 American Home Prod Pyrrold 3,2if quinazoline-1,3-diamine and related compounds
US4118561A (en) * 1977-04-06 1978-10-03 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
JP2005500253A (ja) * 2001-02-23 2005-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物
US7253177B2 (en) * 2004-10-22 2007-08-07 United States Of America As Represented By The Secretary Of The Army Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives
US9920058B2 (en) * 2013-05-06 2018-03-20 Georgia Tech Research Corporation Molecules with potent DHFR binding affinity and antibacterial activity
WO2014205272A1 (en) * 2013-06-20 2014-12-24 Oregon Health & Science University Pyrroloquinazoline compounds
EP3143036B1 (en) * 2014-05-11 2023-08-02 Tel Hashomer Medical Research Infrastructure and Services Ltd. Par-1 based therapeutic conjugates and uses thereof
US11077109B2 (en) * 2017-08-01 2021-08-03 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
US20210161900A1 (en) * 2018-04-30 2021-06-03 Duke University Compositions and methods for the treatment of senescent tumor cells
WO2021035045A1 (en) * 2019-08-20 2021-02-25 City Of Hope Mettl16 inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2023532128A (ja) 2023-07-26
AU2021299504A1 (en) 2023-02-02
US20230295164A1 (en) 2023-09-21
EP4175953A4 (en) 2024-08-14
US20230242540A1 (en) 2023-08-03
CA3183770A1 (en) 2022-01-06
CA3183776A1 (en) 2022-01-06
WO2022006432A1 (en) 2022-01-06
CN115867354B (zh) 2025-08-26
WO2022006447A1 (en) 2022-01-06
JP2023535527A (ja) 2023-08-17
CN116234808B (zh) 2025-11-14
CN115867354A (zh) 2023-03-28
CN116234808A (zh) 2023-06-06
EP4175953A1 (en) 2023-05-10
EP4175958A4 (en) 2024-07-17
EP4175958A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
WO2022006432A1 (en) Compounds having antibacterial activity
CN115433183B (zh) Kras抑制剂及其用途
JP2722280B2 (ja) 二環式アンサマイシン及び抗腫瘍剤としてのそれらの使用
CN100436456C (zh) 具有广谱抗菌作用的含有咪唑并[4,5-b]吡啶甲基的头孢烯化合物
GB2533136A (en) Compounds
WO2020163479A1 (en) Antibiotic ammonium compounds and methods for the treatment of bacterial infections
Yoshizawa et al. S-3578, a new broad spectrum parenteral cephalosporin exhibiting potent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa synthesis and structure-activity relationships
DE69811367T2 (de) Cis-substituierte fluoromethylpyrrolidin-derivate
RU2152948C1 (ru) Диклавулановая соль диаминового эфира и способ ее приготовления
CN108129527B (zh) 依替米星衍生物及其制备方法、其药物组合物和应用
RU2757741C1 (ru) Производное ципрофлоксацина, обладающее антибактериальной активностью в отношении антибиотикоустойчивых штаммов микроорганизмов
US4544501A (en) Bis(2,2-dimethyl-1-aziridinyl)phosphinic amides for use in the treatment of tumors
KR100529815B1 (ko) 피리도벤즈옥사진 유도체 및 이를 포함하는 항균제
CA2328903C (en) Compounds capable of cleaving double-stranded dna and method of utilization of the same
CN114097804A (zh) 一种二氨基嘧啶类化合物在防治农业病原菌中的用途
JPH0114238B2 (enExample)
CA1247094A (en) 7-deazapurine derivatives and their production
KR102765205B1 (ko) 항독력 활성을 가지는 철 킬레이트 화합물 및 이의 용도
DE10216719A1 (de) N-(3-Rifamycinyl)carbamate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Behandlung und Verhütung von Tuberkulose
Tsuzuki et al. Elucidating antibacterial activity of heteroleptic triarylbismuthanes and synthesis of amide derivatives through activated ester intermediate
RU2281286C1 (ru) 11,11-ДИМЕТИЛ-1-ОКСО-1,2,10,11-ТЕТРАГИДРОБЕНЗО [h]ПИРРОЛО[2,1-a]ИЗОХИНОЛИН-2-СПИРО-2-(1-АРИЛ-3-АРОИЛ-4-ГИДРОКСИ-5-ОКСО-2,5-ДИГИДРОПИРРОЛЫ), ПРОЯВЛЯЮЩИЕ АНТИМИКРОБНУЮ АКТИВНОСТЬ ОТНОСИТЕЛЬНО ГРАМПОЛОЖИТЕЛЬНОЙ МИКРОФЛОРЫ
US12616670B2 (en) N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections
US3894061A (en) Anilino derivatives of chelocardin
RU2017744C1 (ru) Способ получения соединений цефема или их кислотно-аддитивных солей
KR100226273B1 (ko) 신규 세팔로스포린계 수용성 유도체 및 그의 제조방법